![]() |
市場調査レポート
商品コード
1549436
ジェネリック医薬品の日本市場の評価:用途別、タイプ別、ブランド別、投与経路別、流通チャネル別、地域別、機会、予測(2018年度~2032年度)Japan Generic Drugs Market Assessment, By Application, By Type, By Brand, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, FY2018-FY2032F |
||||||
カスタマイズ可能
|
ジェネリック医薬品の日本市場の評価:用途別、タイプ別、ブランド別、投与経路別、流通チャネル別、地域別、機会、予測(2018年度~2032年度) |
出版日: 2024年09月06日
発行: Market Xcel - Markets and Data
ページ情報: 英文 125 Pages
納期: 3~5営業日
|
日本のジェネリック医薬品の市場規模は、2024年度の127億2,000万米ドルから2032年度に232億3,000万米ドルに達すると予測され、予測期間(2024年度~2032年度)にCAGRで7.81%の成長が見込まれます。市場の成長は、医療支出を削減する政府の政策、少子化による高齢化の拡大、国内でのジェネリック医薬品の利用を促進するための製薬企業による提携やパートナーシップの高まりによって支えられています。
呼吸器疾患や障害を含む慢性疾患の有病率の増加も、日本のジェネリック医薬品市場の需要を押し上げています。2024年5月にDove Medical Pressに掲載された記事によると、日本における気流閉塞の有病率は3.8%~16.9%です。このことは、ジェネリック医薬品が投与経路、強さ、品質、投与において先発品と同等である一方、患者に経済的な代替手段を提供することから、ジェネリック医薬品への要求を高めています。国の医療支出を削減するため、日本政府もジェネリック医薬品の採用を奨励するさまざまな政策を実施しています。
さらに、医療従事者と患者の両方による製品の利用が増加していることも、ジェネリック医薬品がもたらす恩恵に関する認知度の向上によるものと考えられ、これが日本のジェネリック医薬品の市場規模を押し上げています。さらに、厚生労働省は2022年度の診療報酬改定に向けてジェネリック医薬品を推進する施策を打ち出しました。
さらに、2023年2月にBiomed Centralに掲載された研究では、患者の月収が減少するにつれて、外来での院内処方と院外処方におけるジェネリック医薬品の使用率が増加することが考察されています。
がん、糖尿病、心血管疾患などの疾病の有病率の増加が、ジェネリック医薬品の需要を促進しています。これらの慢性疾患は長期にわたる投薬が必要な場合が多く、ジェネリック医薬品の使用により、患者は費用対効果の高い方法で病状を管理できるため、慢性疾患の管理におけるジェネリック医薬品の重要な役割が明示されています。
政府の後押しによる成長機会
日本政府は、国民の意識を高め、ジェネリック医薬品の利用を促進するための教育キャンペーンへの投資を増やしています。厚生労働省はまた、ジェネリック医薬品の生産を促進し、安定供給を確保するために、大手医薬品メーカーが中小医薬品メーカーと合併することを奨励しています。同省はまた、国内の医薬品開発を加速させるため、製薬産業の活性化も目指しています。医薬品は医療システムの主な経費の1つであり、政府や政策立案者にとって、支出を削減し、医療保障を拡大し、医薬品へのアクセスを改善するために、医薬品のコストを削減することは永遠の課題です。そのため、ジェネリック医薬品の採用が増加し、市場の成長にプラスの影響を与えています。
老年人口の拡大が市場の需要を押し上げる
過去数十年にわたり、高齢化の進行により、医療部門におけるコスト削減のためにジェネリック医薬品への注目が高まっています。World Economic Forumの推計によると、日本人口のほぼ3分の1が65歳以上の高齢者であり、10人に1人以上が80歳以上の高齢者です。高齢者はさまざまな疾患や障害にかかりやすく、定期的に薬を必要とするため、このような増加は国内でのジェネリック医薬品の必要性を高めています。ジェネリック医薬品は、先発医薬品と同じ有効成分を含有しているため、特許医薬品と同じ投与方法、有効性、投与量、効果を持ちながら、経済的に高効率です。そのため、国内ではジェネリック医薬品への選好が高まっています。
ブランドジェネリック医薬品が大きな市場シェアを占める
さまざまな慢性疾患の有病率の増加と市場参入企業による製品上市の増加が、日本のジェネリック医薬品市場の成長を支えています。2023年4月、Mochida Pharmaceutical Co., Ltd.は肺動脈性肺高血圧症を適応症とするTreprost Inhalation Solutionの発売を発表しました。
当レポートでは、日本のジェネリック医薬品市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。
Japan generic drugs market is projected to witness a CAGR of 7.81% during the forecast period FY2024-FY2032, growing from USD 12.72 billion in FY2024 to USD 23.23 billion in FY2032. The market's growth is supported by government policies to reduce healthcare expenditure, expanding aging population due to low birth rates, and rising collaborations and partnerships by pharmaceutical companies to boost the availability of generic drugs in the country.
The growing prevalence of chronic diseases, including respiratory diseases and disorders, is also boosting the Japan generic drugs market demand. According to an article published in Dove Medical Press in May 2024, the prevalence of airflow obstruction in Japan is 3.8%-16.9%. This bolsters the requirement for generics as they are equivalent to their brand-name counterparts in route of administration, strength, quality, and dosage while providing patients with an economical alternative. To reduce the national healthcare expenditure, the Japanese government has also implemented various policies to encourage the adoption of generics.
Additionally, the growing utilization of products by both healthcare professionals and patients can also be attributed to the increasing awareness about the benefits offered by them, which, in turn, is boosting the Japan generic drugs market size. Additionally, the Ministry of Health, Labor and Welfare (MHLW) proposed measures to promote generics for FY2022 reimbursement reform.
Furthermore, a study published in Biomed Central in February 2023 observed that the rate of generic prescription utilization for outpatient in-hospital prescriptions and out-of-hospital prescriptions increased as the monthly personal incomes of patients decreased.
The increasing prevalence of diseases such as cancer, diabetes, and cardiovascular diseases is driving the demand for generic drugs. These chronic conditions often require long-term medication, and the use of generic drugs enables patients to manage their conditions in a cost-effective manner, thereby highlighting the vital role of generic drugs in managing chronic diseases.
Government Encouragement Provides Growth Opportunities
The Japanese government is increasingly investing in educational campaigns to bolster public awareness and boost the utilization of generic drugs. The country's health ministry is also encouraging bigger drug manufacturers to merge with the small ones to propel the production of generics and ensure a stable supply. The ministry also aims to revitalize the pharmaceutical industry to accelerate domestic drug development. Medications are one of the main expenses of the healthcare system; possible reduction in drug costs is an everlasting concern for the government and policymakers to reduce expenditures, extend medical coverage, and improve access to medications. Thus, augmenting the adoption of generic drugs and positively influencing the market's growth.
Expansion of the Aging Population Boosts Market Demand
Over the past few decades, a push toward generic drugs have been witnessed to reduce costs in the healthcare sector due to the growth of the aging population. As per the estimates of the World Economic Forum, almost a third of the Japanese population is older than 65, and more than 1 in 10 individuals in the country are 80 or older. This growth is augmenting the requirement for generic drugs in the country as the older population is more susceptible to various diseases and disorders and regularly needs medications. As the generic drugs carry the same active ingredient as their brand name counterparts, they have the same administration, efficacy, dosage, and effect as the patented drug while being economically efficient. Thus, the preference for generics is increasing in the country.
Branded Generics Account for Major Market Share
The rising prevalence of various chronic diseases and increasing product launches by market players are supporting the growth of the Japan generic drugs market. In April 2023, Mochida Pharmaceutical Co., Ltd. announced the launch of Treprost Inhalation Solution, indicated for pulmonary arterial hypertension. The product contains Treprostinil as the active ingredient. Pulmonary arterial hypertension is characterized by elevated pulmonary artery pressure caused by the hardening and narrowing of pulmonary arteries responsible for carrying blood from the heart to the lungs. Symptoms including dizziness, fatiguability, and palpations accompany the orphan refractory disease. The market players are actively investing in the launch of branded generics to manage and treat such chronic conditions in Japan.
Biosimilars Hold Significant Market Share
Various biosimilars are being launched in Japan to ensure the availability of economically efficient treatment options for patients combatting chronic diseases. In December 2023, Sandoz Group AG and Biocon Biologics Limited announced a partnership for promoting, distributing, and selling Adalimumab in Japan. Under the agreement, Sandoz holds exclusive rights for the distribution and sale of the subcutaneous injection of Adalimumab BS in Japan. Adalimumab, the biosimilar version of Humira, is indicated for rheumatoid arthritis. Such collaborations and partnerships are expected to support the segment's expansion and boost the Japan generic drugs market's growth. The adoption of biosimilars is rapidly increasing in the country due to the growing awareness about their efficacy and safety among the general population.
Future Market Scenario (FY2025-FY2032F)
As per the Japan generic drugs market analysis, the growth of the market is boosted by the ongoing efforts of the Japanese government to propel awareness about generics, the increasing prevalence of chronic diseases, and the rapid aging of the country's population. According to the Population Projections for Japan (2023) in the National Institute of Population and Social Security Research, the number of people of ages 75 and above will increase to 22.58 million in 2030. The increasing investments by pharma companies towards the expansion of their generic portfolios and the launch of new biosimilars in the country are further expected to provide lucrative growth opportunities to the market.
Key Players Landscape and Outlook
Increasing collaborations to ensure a consistent supply of generics in Japan is supporting the market's expansion. Due to the efficacy offered by generic drugs and the assurance of cost efficiency, they are becoming increasingly popular in Japan. In order to ensure their availability, Meiji Seika Pharma, Me Pharma Co., Ltd., and Medreich Limited announced collaboration in July 2023 to establish a sustainable business model for generics. Through this collaboration, the companies are determined to create a unique business model to ensure a steady supply of generic drugs at nominal prices while generating profits for their sustainability. The companies are dedicated towards refining their processes and building rigorous quality control systems to meet all the requirements of Japan.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.